Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D. Society of interventional radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 17, 217-223 (2006)

  • [2]El-Serag HB. Hepatocellular Carcinoma. New Engl J Med 365, 1118-1127 (2011)

  • [3]Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW. Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia. Oncology 81Suppl1, 158-64 (2011)

  • [4]Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S. Review on transarterial chemoembolization in hepatocellular carcinoma:Palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol 72 505-516 (2009)

  • [5]Takayasu K. Transarterial Chemoembolization for Hepatocellular Carcinoma over Three Decades: Current Progress and Perspective,Jpn. J Clin Oncol 42, 247–255 (2012)

  • [6]Cammà C, Schepis F, Orlando A, Albanese M, Shahied L. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224 47-54 (2002)

  • [7]Siskin GP, Dowling K, Virmani R, Jones R, Todd D. Pathologic evaluationof a spherical polyvinyl alcohol embolic agent in a porcine renal model. J Vasc Interv Radiol 14 89-98 (2003)

  • [8]Osuga K, Maeda N, Higashihara H, Hori S, Nakazawa T, Tanaka K. Current status of embolic agents for liver tumor embolization. Int j clinoncol 17(4) 306-315 (2012)

  • [9]Brown KT. Fatal pulmonary complications after arterial embolization with 40-120-lm tris-acryl gelatin microspheres. J Vasc Interv Radiol 15197-200 (2004)

  • [10]Bastian P, Bartkowski R, Köhler H, Kissel T. Chemo-embolization of experimental liver metastases. Part I: distribution of biodegradable microspheres of different sizes in an animal model for the locoregional therapy, Eur J Pharm Biopharm 46, 243-254 (1998)

  • [11]Coldwell DM, Stokes KR, Yakes WF. Embolotherapy: agents, clinical applications, and techniques. Radiographics 14623-643 (1994)

  • [12]Rand T, Loewe C, Schoder M, Schmook MT, Peck-Radosavljevic M, Kettenbach J. Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, lipiodol, and cyanoacrylate. Cardiovasc Intervent Radiol 28, 313-318 (2005)

  • [13]Prajapati HJ, Spivey J R, Hanish SI, El-Rayes BF. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann oncol 24, 965-973 (2013)

  • [14]Moschouris H, Malagari K, Papadaki MG, Kornezos I, Matsaidonis D. Contrast-enhanced ultrasonography of hepatocellular carcinoma after chemoembolisationusing drug-eluting beads: apilot study focused on sustained tumor necrosis. Cardiovasc Inter Radiol 33, 1022-1027 (2010)

  • [15]Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. Am J Roentgenol 197(4) W562-W570 (2011)

  • [16]Sottani C, Poggi G, Quaretti P, Regazzi M, Montagna B, Quaquarini E, Imbriani M. Serum pharmacokinetics in patients treated with transarterialchemoembolization (TACE) using two types of epirubicin-loaded microspheres. Anticancer Res 321769-1774 (2012)

  • [17]Song MJ, Chun HJ, Song do S, Kim HY, Yoo SH. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 57, 1244-1250 (2012)

  • [18]Wang X, Xue J, Huang Y, Zhi X. Preparation, burst release and influencing factors of poly(lactic-co-glycolic acid) micro-spheres. J CRTER 15(34), 6395-6398 (2011)

  • [19]Brown DB, Pilgram TK, Darcy MD, Fundakowski CE. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 16 1661-1666 (2005)

  • [20]Spies JB, Allison S, Flick P, Cramp M. Spherical polyvinyl alcohol versus tris-acryl gelatin microspheres for uterine artery embolization for leiomyomas: results of a limited randomized comparative study. J Vasc Interv Radiol 16, 1431-1437 (2005)

  • [21]van Malenstein H, Maleux G, Vandecaveye V, Heye S, Laleman W, van Pelt J, Vaninbroukx J, Nevens F, Verslype C. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 34, 368–376 (2011)

  • [22]Bonomo G, Pedicini V, Monfardini L, Della Vigna P. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up,Cardiovasc. Intervent Radiol 33, 552-559 (2010)

  • [23]Kirchhoff TD, Bleck JS, Dettmer A, Chavan A, Rosenthal H. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. HBPD Int 6, 259-266 (2007)

  • [24]Liu H, Fan H, Cui Y, Chen Y, Yao K, Goh JC. Effects of the controlled-released basic fibroblast growth factor from chitosan–gelatin microspheres on human fibroblasts cultured on a chitosan–gelatin scaffold. Biomacromolecules 8, 1446-1455 (2007)

  • [25]Mao S, Xu J, Cai C, Germershaus O, Schaper A, Kissel T. Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres. Int J Pharm 334 (1-2), 137-148 (2007)

  • [26]Patil SD, Papadmitrakopoulos F, Burgess DJ. Concurrent delivery of dexametha-sone and VEGF for localized in flammation co ntrol and angiogenesis. J Con troll Release 117, 68-79 (2007)

  • [27]Zolnik BS, Burgess DJ. Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. J Control Release 127, 137-145 (2008)

  • [28]Li G, Chen W, Feng H, Zheng C. Flameless atomic absorption spectrometric determination of cisplatincontent in cisplatinbletillastriatamicrospheres for targeting drug delivery. Chin J Spectr Lab 5 (1998)

  • [29]Li J, Pu Y, Wang S, Ding M, Chen D, Zhu M. Pharmacokinetic study and effectiveness evaluation of slow-release PLGA-5-fluorouracil microsphere. Cancer Chemoth Pharm 71, 351-359 (2013)

  • [30]Urushizaki F, Yamaguchi H, Nakamura K, Namajiri S, Sugibayashi K, Morimoto Y. Swelling and mechanical properties of poly(vinyl alcohol) hydrogels. Int J Pharm 58, 135-142 (1990)

  • [31]Kulkarni RK, Pani KC, Neuman C, Leonard F. Polylactic acid for surgical for surgical implants. Arch Surg-Chicago 93, 839-843 (1966)

  • [32]Cutright DE, Hunsuck EE. Tissue reaction to the biodegradable polylactic acid suture. J Oral Maxil Surg 31, 134-139 (1971)

  • [33]Cutright DE, Hunsuck EE, Beasley JD. Fracture reduction using a biodegradable material. J Oral Maxil Surg 29, 393-397 (1971)

  • [34]Pekarek KJ, Jacob JS, Mathiowitz E. Double-walled polymer microspheres for controlled drug release. Nature 367, 258-260 (1994)

  • [35]Crotts G, Park TG. Preparation of porous and nonporous biodegradable polymeric hollow microspheres. J Control Release 35 (2) 91-105 (1995)

  • [36]Pekarek KJ, Dyrud MJ, FerrerK, Jong YS, Mathiowitz E. In vitro and in vivo degradation of double-walled polymer microspheres. J Control Release 40, 169-178 (1996)

  • [37]Hollinger JO, Brekke J, Gruskin E, Lee D. Role of bone substitutes. Clin Orthop Relat R 324, 55-65. (1996)

  • [38]Leach KJ, Mathiowitz E. Degradation of double-walled polymer microspheres of PLLA and P(CPP: SA)20:80. I. In vitro degradation. Biomaterials 19(21), 1973-1980 (1998)

  • [39]Sturesson C, Carlfors J. Incorporation of protein in PLG-microspheres with retention of bioactivity. J Control Release 67, 171-178 (2000)

  • [40]Yang YY, Chi HH, Chung TS. Effect of preparation temperature on the characteristics and release profiles of PLGA microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. J Control Release 69(1), 81-96 (2000)

  • [41]Yang YY, Chung TS, Ng NP. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 22(3), 231-241 (2001)

  • [42]Lee TH, Wang J, Wang CH. Double-walled microspheres for the sustained release of a highly water soluble drug: characterization and irradiation studies. J Control Release 437, 437-452 (2002)

  • [43]Kim TK, Burgess DJ. Formulation and release characteristics of poly(lactic-co-glycolic acid) microspheres containing chemically modified protein. J Pharm Pharmacol 53, 23-31 (2001)

  • [44]Astete CE, Sabliov C.M. Synthesis and characterization of PLGA nanoparticles. J Biomat Sci-Polym E 17(3), 247-289 (2006)

  • [45]Shen ZR, Zhu JH, Wu LT. Preparation of poly(lactic acid) microspheres containing 5-fluorouracil and tests of drug release in vitro/in vivo. Chin J Pharm 26(7), 305-309 (1995)

  • [46]Makino K, Nakajima T, Shikamura M, Ito F, Ando S. Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin. Colloid Surfaces B 36(1), (2004) 35-42.

  • [47]Bae SE, Son JS, Park K, Han DK. Fabrication of covered porous PLGA microspheres using hydrogen peroxide for controlled drug delivery and regenerative medicine. J Control Release 133(1), 37-43 (2009)

  • [48]Rosca ID, Fumio W, Motohiro U. Microparticle formation and its mechanism in single and double emulsion solvent evaporation. J control Release 99(2), 271-280 (2004)

  • [49]Chen YJ, Xu XY, Zhou JP. Research advance of PLGA microspheres. Acta Chin Pharm Univ 38(2), 186-189 (2007)

  • [50]Mi F, Lin Y, Wu Y, Shyu S, Tsai Y. Chitin/PLGA blend microspheres as a biodegradable drug-delivery system: phase-separation, degradation and release behavior. Biomaterials 23(15), 3257-3267 (2002)

  • [51]Jain RA. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide)(PLGA) devices. Biomaterials 21(23), 2475-2490 (2000)

  • [52]Giunchedi P, Conti B, Genta I, Conte U, Puglisi G. Emulsion spray-drying for the preparation of albumin-loaded PLGA microspheres. Drug DevInd Pharm 27(7), 745-750 (2001)

  • [53]Furlan M, Kluge J, Mazzotti M, Lattuada M. Preparation of biocompatible magnetite–PLGA composite nanoparticles using supercritical fluid extraction of emulsions. J Supercrit Fluid 54(3), 348-356 (2010)

  • [54]Williams JR, Clifford AA, Al-Saidi SHR. Supercritical fluids and their applications in biotechnology and related areas. Mol Biotechnol 22, 263-286 (2002)

  • [55]Jung J, Perrut M. Particle design using supercritical fluids: literature and patent survey. J Supercrit Fluid 20, 179-219 (2001)

  • [56]Ginty PJ, Whitaker MJ, Shakesheff KM, Howdle SM. Drug delivery goes supercritical. Mater Today 8, 42-48 (2005)

  • [57]Shiga K, Muramatsu N, Kondo T. Preparation of Poly (D, L-lactide) and Copoly (lactide-glycolide) Microspheres of Uniform Size. J Pharm Pharmac 48(9), 891-895 (1996)

  • [58]Gasparini G, Kosvintsev SR, Stillwell MT, Holdich RG. Preparation and characterization of PLGA particles for subcutaneous controlled drug release by membrane emulsification. Colloid Surface B 61(2), 199-207 (2008)

  • [59]Ma G, Nagai M, Omi S. Preparation of uniform poly (lactide) microspheres by employing the Shirasu Porous Glass (SPG) emulsification technique. Colloid Surface A 153(1), 383-394 (1999)

  • [60]Sawalha H, Purwanti N, Rinzema A, Schroën K, Boom R. Polylactide microspheres prepared by premix membrane emulsification—Effects of solvent removal rate. J Membrane Sci 310(1), 484-493 (2008)

  • [61]Liu W, Yang X, Ho WSW. Preparation of uniform-sized multiple emulsions and micro/nano particulates for drug delivery by membrane emulsification. J Pharm Sci 100(1), 75-93 (2011)

  • [62]Flandroy P, Grandfils C, Daenen B, Snaps F, Dondelinger RF, Jérôme R, Bassleer R, Heinen E. In vivo behavior of poly(D,L)-lactide microspheres designed for chemoembolization. J Control Release 44(23), 153-170 (1997)

  • [63]Ding H, Zhang S, Shen WW. Research and preparation of arterial cisplatin embolic microsphere. J Shan Medic Univ 30(1), 206-207 (1999)

  • [64]Sakatoku M, Hirana M, Yamashita R, Yamada T, Kawaura Y, Iwa T. A new anticancer preparation, 5-fluorouracil-poly-L-lactic acid microcapsule, and its therapeutic evaluation. Nihon Geka Gakkai zasshi 87(2), 133-140 (1986)

  • [65]Liu ZK, Wei SL, Lan CQ. Hepatic embolization and proterty of poly(lactic acid) microspheres containing cisplatin. Act Pharm Sin 28(10) 792-797 (1993)

  • [66]Chen H, Li Q, Chen Q. The role of Tanshinone A-Polylactic Acid/Glycolic Acid Microspheres in rabbit transcatheter embolization. J Interv Radiol 19(12), 977-981 (2010)

  • [67]Zhong Y, Wang X, Zhang G. Visualized iodized oil-5-fluorouracil loaded polylactic acid microsphere preparation and preparation method thereof. Acad J Sec Mili Med Univ 8668, 10-15 (2010)

  • [68]Vente MAD, Nijsen JFW, Wit TCDe, Seppenwoolde JH, Krijger GC. Clinical effects of transcatheter hepatic arterial embolization with holmium-166 poly(L-lactic acid) microspheres in healthy pigs. Eur J Nucl Med MolI 35(7) 1259-1271 (2008)

  • [69]Vente MAD, Nijsen JFW, De Roos R, Van Steenbergen MJ, Kaaijk CNJ. Neutron activation of holmium poly (L-lactic acid) microspheres for hepatic arterial radioembolization: a validation study. Biomed Microdevices 11(4), 763-772. (2009)

  • [70]Smits MLJ, Nijsen JFW, van den Bosch MA, Lam MGEH, Vente MAD, Mali WPTM. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase, dose-escalation study. Lancet Oncol 13(10), 1025-1034. (2012)

  • [71]Tam KY, Leung KC, Wang YJ. Chemoembolization agents for cancer treatment. Eur J Pharm Sci 44(1) 1-10 (2011)

  • [72]Han S, Zhang X, Zou L, Lu C, Zhang J, Li J, Li M. Does Drug-Eluting Bead Transcatheter Arterial Chemoembolization Improve the Management of Patients with Hepatocellular Carcinoma? A Meta-Analysis, PLOS ONE 9(8), e102686 (2014)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jun 2016Review
Progress in research and application of PLGA embolic microspheres
Shilong Han 1, Xiaoping Zhang 2, Maoquan Li 1,2,*
Affiliations
Article Info

1 Department of Interventional and Vascular Surgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, 200072, China

2 Institute of Medical Intervention Engineering, Tongji University, Shanghai, 200072, China

Abstract

Transcatheter arterial chemoembolization was an important method in the treatment of solid cancers and the effectiveness of such treatment depends on the nature of embolic agent. Due to the biocompatibility, controllable degradation rate, and both hydrophobicity–hydrophilicity, researches of application on poly(lactic-co-glycolic acid) (PLGA) in medical practice has been ongoing for more than 40 years. We have seen many benefits for patients in recent years. There were five different methods of preparing micrometer-scale microspheres, and three kinds of PLGA microspheres have been subjected to experimental research or used in clinical applications, namely blank microspheres, drug-loaded microspheres, and radioactive microspheres. Hereby, we reviewed the production and clinical and experimental applications of PLGA microspheres in practice.

Keywords

  • PLGA
  • Microsphere
  • Embolization
  • Biodegradable
  • Review

References